Your session is about to expire
← Back to Search
Sirolimus for Post-COVID Fibrosis Prevention
Study Summary
This trialseeks to find out if a drug can stop COVID-19 pneumonia from leading to lung scarring.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your chest CT scan shows less than 10% lung scarring.I have not had worsening or unstable brain or nerve conditions.I have cancer or an active infection that is not COVID-19, including untreated TB.I have not had serious heart problems or treatments in the last 6 months.I am not pregnant or breastfeeding and will use birth control during the trial.I need extra oxygen of at least 5 liters per minute or 40% oxygen concentration.I can sign the consent form myself or have someone legally authorized to do so.I am currently in the hospital.I have been diagnosed with pulmonary fibrosis or interstitial lung disease.You have had a bad reaction to sirolimus in the past.You have a positive test for an active COVID-19 infection.I am 18 years old or older.I have been diagnosed with COVID-19 pneumonia.I am not taking drugs that strongly affect liver enzyme CYP3A4.
- Group 1: Sirolimus 0.5mg
- Group 2: Sirolimus 1mg
- Group 3: Sirolimus 2mg
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the magnitude of recruitment for this clinical research?
"Correct. Details found on clinicaltrials.gov verify that this medical study, which was originally posted on July 9th 2021, is actively recruiting participants. Approximately 60 people are needed to be recruited from a single site."
Could you please elucidate the past experiments utilizing Sirolimus 1mg?
"Currently, there are 125 ongoing medical studies surrounding Sirolimus 1mg with 13 trials in Phase 3. Although most of these clinical trials take place in the city of Cincinnati, Ohio; globally speaking, 1074 different sites have active research for this drug."
In what medical conditions is Sirolimus 1mg typically administered?
"Sirolimus 1mg is usually administered to combat organ transplant rejection and certain liver diseases. It also has potential for treating kidney disease and renal angiomyolipomas."
Are there any vacant slots for participants in the experiment?
"Per the records on clinicaltrials.gov, this investigation is actively searching for participants with a commencement date of July 9th 2021 and most recent edition made on November 18th 2022."
Share this study with friends
Copy Link
Messenger